Maitake and immune markers
What 2 graded rows on maitake agree on for immune markers, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Maitake page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Maitake page, with its PubMed record.
Your question
Maitake and immune markers
2 rows · 52 peopleSplit. 1 row found an improvement and 1 had mixed results.
- DGrade D× 2
- Rows
- 2
- Trials
- 2
- People
- 52
What the rows share
From the rowsThe best-graded row, grade D, is an open-label trial of 34 people (2009) and reported mixed results.
The rows run from 18 to 34 people, published from 2009 to 2015: 2 single studies.
The rows
1 improved · 1 mixed- DGrade DNeutrophil and monocyte function in myelodysplastic syndrome · Improved
Open-label trial · n 18 · 2015 · Adults with low- or intermediate-1-risk myelodysplastic syndrome (21 enrolled)
3 mg/kg twice a day · 12 weeks
Lab measures of neutrophil and monocyte function rose; well tolerated, with asymptomatic eosinophilia in 4 people.
- DGrade DImmune measures in blood after breast cancer treatment · Mixed
Open-label trial · n 34 · 2009 · Postmenopausal women free of disease after breast cancer treatment
0.1 to 5 mg/kg twice a day (sequential dose-escalation cohorts) · 3 weeks
No dose-limiting toxicity; some immune measures rose and others fell, with no simple dose response.